Kyowa Kirin, Inc.

The study examines real-world treatment patterns for Sézary syndrome (SS) in the US from 2018 to 2020, identifying increased use of systemic treatments, particularly mogamulizumab, and variations in treatment patterns across states. The COVID-19 pandemic impacted treatment selection, with a notable drop in ECP and oral systemic therapies in Q2 2020. Despite limitations in data source and completeness, the findings highlight the complexity of therapeutic decision-making for SS.

AstraZeneca's Fasenra receives FDA approval for EGPA treatment in the US, based on the MANDARA Phase 3 trial. Fasenra showed comparable efficacy to mepolizumab, with 60% remission rate and 41% OCS taper success.

China's NMPA grants GSK's Blenrep breakthrough therapy designation for relapsed or refractory multiple myeloma treatment, based on Phase III DREAMM-7 trial results showing significant PFS improvements.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.

CRISPR-Cas9 gene editing therapy Casgevy, approved for sickle cell disease, faces slow patient treatment and profitability challenges. 20 patients are 'in the funnel' but timeline for treatment remains unclear. Insurance coverage for Casgevy's $2.2 million price is uncertain, with commercial payers likely to cover first. Fertility treatments not covered by Medicare/Medicaid add complexity. Future gene therapies need streamlined manufacturing and robust clinical data for market success.